Eptifibatide Injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia.2025.5.20
2025-11-18 10:25
Eptifibatide Injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia.
Product detail
The name of the drug: Eptifibatide Injection
Dosage form: Sterile injection
Strength: 20mg/10mL、75mg/100mL
Indication: It is indicated for patients undergoing non-emergent percutaneous coronary intervention (PCI) with intracoronary stent implantation; it is also indicated for the treatment of patients with unstable angina pectoris or non-Q-wave myocardial infarction.
The marketing authorization for Eptifibatide Injection issued by Australia's Therapeutic Goods Administration (TGA) this time indicates that the company's Eptifibatide Injection has obtained the qualification to be sold in Australia. This will help the company expand its overseas markets, enhance the market competitiveness of its products, and facilitate the healthy, long-term and stable development of the company.
